Trials / Unknown
UnknownNCT05989867
Evaluation of OGTT in Patients With Post-pancreatitis Diabetes Mellitus for Diagnosis and Characterization
Evaluation of Oral Glucose Tolerance Testing in Patients With Post-pancreatitis Diabetes Mellitus for Diagnosis and Characterization: a Cross-sectional Trial
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 15 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the islet function and insulin secretion pattern of post-pancreatitis diabetes mellitus by oral glucose tolerance testing, and to explore the pathophysiological characteristics of PPDM-C which provide evidence for the diagnosis of PPDM-C.
Detailed description
Blood samples will be collected from patients with chronic pancreatitis by oral glucose tolerance test (steamed bun meal test, SBMT) to assess their pancreatic islet function and insulin secretion pattern, measure other intestinal hormones, exosomes, plasma metabolites, and serum biochemical factors to characterize the pathophysiological features of PPDM-C and provide evidence for the diagnosis of PPDM-C. In order to better understand the glycemic fluctuations in patients with chronic pancreatitis combined with diabetes and guide subsequent treatment, Continuous Glucose Monitoring would be used in patients with chronic pancreatitis who had new-onset diabetes or poor glycemic control.
Conditions
- Chronic Pancreatitis
- Pancreatogenic Type 3C Diabetes Mellitus
- Diabetes Mellitus
- Oral Glucose Tolerance Test
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | blood test | Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis. Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors |
| DEVICE | Continuous Glucose Monitor | blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control ) |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-12-01
- Completion
- 2025-03-01
- First posted
- 2023-08-14
- Last updated
- 2023-08-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05989867. Inclusion in this directory is not an endorsement.